NSPR Key Statistics, Chart & Performance
The current stock price of NSPR is 1.72 USD. In the past month the price decreased by -8.99%. In the past year, price decreased by -37.68%.
NSPR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| COO | COOPER COS INC/THE | 20.21 | 16.59B | ||
| SOLV | SOLVENTUM CORP | 14.5 | 14.94B | ||
| ALGN | ALIGN TECHNOLOGY INC | 17.87 | 12.40B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.22 | 5.12B | ||
| LNTH | LANTHEUS HOLDINGS INC | 11.34 | 4.48B | ||
| HAE | HAEMONETICS CORP/MASS | 17.09 | 3.84B | ||
| ICUI | ICU MEDICAL INC | 19.22 | 3.78B | ||
| XRAY | DENTSPLY SIRONA INC | 8.09 | 2.55B | ||
| NEOG | NEOGEN CORP | 33.17 | 2.09B | ||
| UFPT | UFP TECHNOLOGIES INC | 29.84 | 1.99B | ||
| STAA | STAAR SURGICAL CO | N/A | 1.10B | ||
| EMBC | EMBECTA CORP | 4.3 | 746.59M |
Related stock screener links
About NSPR
Company Profile
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
Company Info
INSPIREMD INC
6303 Waterford District Drive, Suite 215
Miami FLORIDA 6744832 US
CEO: Marvin Slosman
Employees: 86
Phone: 18887766804
INSPIREMD INC / NSPR FAQ
What does INSPIREMD INC do?
InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The company is headquartered in Miami, Florida and currently employs 85 full-time employees. The company went IPO on 2013-04-12. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.
What is the current price of NSPR stock?
The current stock price of NSPR is 1.72 USD. The price decreased by -6.52% in the last trading session.
What is the dividend status of INSPIREMD INC?
NSPR does not pay a dividend.
How is the ChartMill rating for INSPIREMD INC?
NSPR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting NSPR stock to perform?
8 analysts have analysed NSPR and the average price target is 4.08 USD. This implies a price increase of 137.21% is expected in the next year compared to the current price of 1.72.
Should I buy NSPR stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on NSPR.
Who owns INSPIREMD INC?
You can find the ownership structure of INSPIREMD INC (NSPR) on the Ownership tab.
NSPR Technical Analysis
NSPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to NSPR. NSPR has a great financial health rating, but its profitability evaluates not so good.
NSPR Financial Highlights
Over the last trailing twelve months NSPR reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS decreased by -12% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.87% | ||
| ROE | -72.05% | ||
| Debt/Equity | 0 |
NSPR Forecast & Estimates
8 analysts have analysed NSPR and the average price target is 4.08 USD. This implies a price increase of 137.21% is expected in the next year compared to the current price of 1.72.
For the next year, analysts expect an EPS growth of -10.5% and a revenue growth 22.32% for NSPR